Zaltrap (ziv-aflibercept IV) / Sanofi 
Welcome,         Profile    Billing    Logout  
 176 Diseases   9 Trials   9 Trials   1479 News 
14 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zaltrap (ziv-aflibercept IV) / Sanofi
2017-003509-16: Serum cytokine levels as predictors of the efficacy of aflibercept in combination with FOLFIRI in metastatic Colo-Rectal Cancer patients (mCRC) Livelli sierici di citochine come predittori di efficacia di aflibercept in combinazione con FOLFIRI in pazienti con Cancro al Colon-Retto metastatico

Ongoing
4
124
Europe
Concentrate for solution for infusion, ZALTRAP - 25 MG/ML - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONE (VETRO) - 100 MG/4 ML - 1 FLACONE
FONDAZIONE RICERCA TRASLAZIONALE (FORT), Sanofi S.p.A.
Metastatic Colo-Rectal Cancer Cancro al Colon-Retto metastatico, Metastatic Colo-Rectal Cancer Cancro al Colon-Retto metastatico, Diseases [C] - Cancer [C04]
 
 
2020-002533-14: Targeted therapy for advanced colorectal cancer patients. Terapia mirata per il trattamento dei pazienti con carcinoma metastatico del colon-retto.

Ongoing
4
106
Europe
Oxaliplatino, Irinotecan, Cetuximab, Panitumumab, Capecitabina, Bevacizumab, Fluorouracile, Calcio Folinato, ZALTRAP, [L01XA 03], [L01XX19], [L01XC06], [L01XC08], [L01BC06], [L01XC07], [L01BC02], [V03AF03], [L01XX44], Concentrate and solvent for concentrate for solution for infusion, Concentrate for solution for injection/infusion, Solution for injection/infusion, Film-coated tablet, Concentrate for solution for infusion, Powder for solution for injection
DIP. MEDICINA DEI SISTEMI UNIVERSITà DEGLI STUDI DI ROMA TOR VERGATA, Unione Europea, Horizon 2020
unresectable metastatic colorectal cancer (mCRC) carcinoma del colon-retto metastatico (mCRC) non operabile, colorectal cancer Tumore del colon- retto, Diseases [C] - Cancer [C04]
 
 
NCT04810585: Plasma Biomarker for Aflibercept in Advanced Colorectal Cancer

Recruiting
4
153
RoW
Aflibercept + FOLFIRI
Yonsei University
Recurrent or Metastatic Colorectal Cancer
10/25
10/25
TWICE-IRI, NCT04392479: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study.

Active, not recruiting
3
202
Europe
Aflibercept-FOLFIRI, ZALTRAP-FOLFIRI, Aflibercept-mFOLFIRI3, ZALTRAP- mFOLFIRI3
GCS IHFB Cognacq-Jay, Fondation ARCAD
Cancer Colorectal, Metastasis
06/23
06/24
2013-004081-33: EFFICACY AND SAFETY of aflibercept ASSOCIATED WITH A FOLFIRI CHEMOTHERAPY IN 1ST LINE TREATMENT OF PATIENTS SUFFERING FROM METASTATIC COLORECTAL CANCER Phase II - single arm - multicenter EFFICACITE ET TOLERANCE DE L’AFLIBERCEPT ASSOCIE A UNE CHIMIOTHERAPIE PAR FOLFIRI EN 1ERE LIGNE DE TRAITEMENT CHEZ DES PATIENTS ATTEINTS D’UN CANCER COLORECTAL METASTATIQUEPhase II monobras - multicentrique

Not yet recruiting
2
54
Europe
Aflibercept, Concentrate for solution for infusion, Zaltrap
Fédération Francophone de Cancérologie Digestive (FFCD), Sanofi-Aventis Group
Metastatic colorectal cancer Cancer colorectal métastatique, Metastatic colorectal cancer Cancer colorectal métastatique, Diseases [C] - Cancer [C04]
 
 
2006-006144-55: A multicenter, open-label, single-arm, two-stage study of the efficacy and safety of AVE0005 (VEGF Trap) administered intravenously every 2 weeks in patients with platinum- and erlotinib-resistant, locally advanced or metastatic non-small-cell lung adenocarcinoma.

Ongoing
2
20
Europe
AVE0005,
sanofi-aventis recherche & développement
patients with platinum- and erlotinib-resistant, locally advanced or metastatic non-small-cell lung adenocarcinoma.
 
 
2016-004575-49: A multicenter randomized phase 2 study to compare the efficacy and safety of avelumab versus standard second line treatment, in patients with metastatic colorectal cancer (MMR) after first line treatment progression.

Ongoing
2
118
Europe
Anti PD-L1, Avelumab, Concentrate for solution for infusion, Solution for infusion, ELVORINE, FLUOROURACILE EBEWE, ELOXATINE, CAMPTO, Avastin, Erbitux, Vectibix, ZALTRAP
Federation Francophone de Cancerologie Digestive, Merck
COLORECTAL METASTATIC CANCER WITH MICROSATELLITE INSTABILITY (MSI), COLORECTAL METASTATIC CANCER WITH specific molecular alteration (MSI), Diseases [C] - Cancer [C04]
 
 
2017-000329-11: Comparison of a standard chemotherapy (FOLFOX) with a combination of Aflibercept and 5FU for elderly or frail elderly patients with metastatic colorectal cancer

Not yet recruiting
2
124
Europe
Aflibercept, Concentrate for solution for infusion, Zaltrap
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Sanofi
metastatic colorectal cancer, metastatic colorectal cancer, Diseases [C] - Cancer [C04]
 
 
NCT01782443: Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors

Completed
2
19
US
Ziv-aflibercept
Dana-Farber Cancer Institute
Carcinoid Tumor
03/21
12/21
NCT06121180: Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma

Recruiting
2
32
US
ZIV-Aflibercept, Zaltrap, Eylea, Cemiplimab, Libtayo
H. Lee Moffitt Cancer Center and Research Institute, Genzyme, a Sanofi Company, Regeneron Pharmaceuticals
Metastatic Uveal Melanoma
10/30
10/30
NCT06047379: Safety and Efficacy of NEO212 in Patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Recruiting
1/2
134
US
NEO212 Oral Capsule, POH-TMZ, Ipilimumab, Yervoy, Pembrolizumab, Keytruda, Nivolumab, Opdivo, Regorafenib, Stivagra, Carboplatin, Paraplatin, Paclitaxel, Taxol, FOLFIRI Protocol, Zaltrap, Bevacizumab, Avastin, Mvasi, Zirabev, Alymsys, Vegzelma
Neonc Technologies, Inc.
Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Microsatellite Instability-High Solid Malignant Tumor, Mismatch Repair Deficient Solid Malignant Tumor, Microsatellite Instability-High Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Small Cell Lung Cancer, Squamous Cell Carcinoma, Urothelial Carcinoma
02/26
08/26
NCT02159989: Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Completed
1
83
US
Sapanisertib, INK-128, INK128, MLN-0128, MLN0128, TAK-228, Ziv-Aflibercept, Aflibercept, AVE0005, Eylea, Vascular Endothelial Growth Factor Trap, VEGF Trap, VEGF Trap R1R2, VEGF-Trap, Zaltrap
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Fibrolamellar Carcinoma, Metastatic Malignant Solid Neoplasm, Ovarian Carcinoma, Pancreatic Neuroendocrine Tumor, Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Solid Neoplasm
06/21
01/24
NCT02298959: Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer

Active, not recruiting
1
78
Canada, US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Elastography, MRE, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, Pembrolizumab Biosimilar RPH-075, QL2107, RPH 075, RPH-075, RPH075, SCH 900475, SCH-900475, SCH900475, Ziv-Aflibercept, Aflibercept, Aflibercept beta, AVE0005, Eylea, Vascular Endothelial Growth Factor Trap, VEGF Trap, VEGF Trap R1R2, VEGF-Trap, Zaltrap
National Cancer Institute (NCI)
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Colorectal Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Ovarian Carcinoma, Metastatic Renal Cell Carcinoma, Platinum-Resistant Ovarian Carcinoma, Recurrent Melanoma, Recurrent Renal Cell Carcinoma, Refractory Melanoma, Refractory Renal Cell Carcinoma, Sarcoma, Stage IV Colorectal Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
12/25
12/25
NCT05178745: A Prospective Observational Cohort Study Evaluating Resection Rate in Patients With Metastatic Colorectal Cancer Treated With Aflibercept in Combination With FOLFIRI - Observatoire résection

Completed
N/A
140
NA
Fluorouracil, Aflibercept, ZALTRAP®, Irinotecan, CAMPTOSAR®
Sanofi
Metastatic Colorectal Cancer, Colorectal Neoplasms
05/22
05/22

Download Options